Janus Henderson Investors US’s Alnylam Pharmaceuticals ALNY Stock Holding History

Janus Henderson Investors US’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$33.3M	Buy	649,399 +131,969	+26%	+$6.1M	0.03%	523
2016 Q4	$19.4M	Buy	517,430 +18,393	+4%	+$770K	0.02%	619
2016 Q3	$33.8M	Buy	499,037 +140,915	+39%	+$9.94M	0.03%	507
2016 Q2	$19.9M	Buy	358,122 +322,622	+909%	+$20.3M	0.02%	576
2016 Q1	$2.23M	Buy	35,500 +14,200	+67%	+$944K	﹤0.01%	896
2015 Q4	$2M	Sell	21,300 -37,100	-64%	-$3.44M	﹤0.01%	943
2015 Q3	$4.69M	Sell	58,400 -16,600	-22%	-$1.84M	﹤0.01%	839
2015 Q2	$8.99M	Buy	75,000 +6,800	+10%	+$813K	0.01%	714
2015 Q1	$7.12M	Buy	68,200 +55,800	+450%	+$5.65M	0.01%	735
2014 Q4	$1.2M	Buy	+12,400	New	+$1.15M	﹤0.01%	958

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Janus Henderson Investors US's ALNY Position: Q1 2017 in Review

Janus Henderson Investors US increased its Alnylam Pharmaceuticals (ALNY) stake by 26% in Q1 2017, buying an estimated $6.1M and bringing the position to 649,399 shares worth $33.3M. The position accounts for 0.03% of the portfolio, ranked #523.

Janus Henderson Investors US first reported a position in ALNY in Q4 2014 and has held it in 10 quarters since. The position peaked at $33.8M in Q3 2016. 199 funds tracked by Wall St. Rank hold ALNY as of Q1 2017.

Janus Henderson Investors US held 649,399 shares of Alnylam Pharmaceuticals worth $33.3M as of Q1 2017.
Janus Henderson Investors US bought 131,969 Alnylam Pharmaceuticals shares in Q1 2017, an estimated $6.1M.
Alnylam Pharmaceuticals made up 0.03% of Janus Henderson Investors US's portfolio in Q1 2017, its #523 holding.
Janus Henderson Investors US first reported a position in Alnylam Pharmaceuticals in Q4 2014 and has held it in 10 quarters since.
Janus Henderson Investors US's Alnylam Pharmaceuticals position peaked at $33.8M in Q3 2016.
199 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2017.

Based on Janus Henderson Investors US's 13F filing for Q1 2017, filed 16 May 2017.